Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a " standard chemotherapy regimen" : The CASA randomized trial

Breast

Volumn 22, Issue 2, 2013, Pages 130-137

  Crivellari, Diana ^a   Gray, Kathryn P ^b,c   Dellapasqua, Silvia ^d   Puglisi, Fabio ^e   Ribi, Karin ^f   Price, Karen N ^g,h   Láng, István ⁱ   Gianni, Lorenzo ^j   Spazzapan, Simon ^a   Pinotti, Graziella ^k   Lüthi, Jean Marc ^l   Gelber, Richard D ^b,c,h,m   Regan, Meredith M ^b,m   Colleoni, Marco ^d   Castiglione Gertsch, Monica ⁿ   Maibach, Rudolf ^f   Rabaglio, Manuela ^f,o   Coates, Alan S ^p   Goldhirsch, Aron ^d  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f International Breast Cancer Study Group Coordinating Center   (Switzerland)

^g International Breast Cancer Study Group Statistical Center   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^j DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^k OSPEDALE DI CIRCOLO   (Italy)

^l Spital Thun STS AG   (Switzerland)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ UNIVERSITY OF GENEVA   (Switzerland)

^o UNIVERSITY OF BERN   (Switzerland)

^p UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Adjuvant treatment; Breast cancer; Chemotherapy; Elderly; Endocrine nonresponsive; Pegylated liposomal doxorubicin

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; METHOTREXATE; PROGESTERONE RECEPTOR;

AGED; ALOPECIA; ANOREXIA; ANXIETY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CHEMOTHERAPY INDUCED EMESIS; COGNITION; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; FEMALE; FEMUR FRACTURE; FOLLOW UP; GASTRITIS; HAIR LOSS; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; METRONOMIC DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; OSTEOPOROSIS; PAIN; PHASE 3 CLINICAL TRIAL; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STOMATITIS; THROMBOSIS; THROMBUS; UROGENITAL TRACT DISEASE;

EID: 84875514759     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.01.015     Document Type: Article

References (35)

1. Wildiers H., Kunkler I., Biganzoli L., Fracheboud J., Vlastos G., Bernard-Marty C., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007, 8:1101-1115.
2. Muss H.B., Berry D.A., Cirrincione C., Budman D.R., Henderson I.C., Citron M.L., et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 2007, 25:3699-3704.
3. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
4. Muss H.B., Berry D.A., Cirrincione C.T., Theodoulou M., Mauer A.M., Kornblith A.B., et al. CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009, 360:2055-2065.
5. Giordano S.H., Duan Z., Kuo Y.F., Hortobagyi G.N., Goodwin J.S. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006, 24:2750-2756.
6. Munzone E., Di Pietro A., Goldhirsch A., Minchella I., Verri E., Cossu Rocca M., et al. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast 2010, 19:33-37.
7. Colleoni M., Rocca A., Sandri M.T., Zorzino L., Mascil G., Nole F., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13:73-80.
8. Hürny C., Bernhard J., Coates A., Peterson H.F., Castiglione-Gertsch M., Gelber R.D., et al. Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care 1996, 34:234-248.
9. Hürny C., Bernhard J., Bacchi M., van Wegberg B., Tomamichel M., Spek U., et al. The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1993, 4:200-208.
10. Bernhard J., Lowy A., Mathys N., Hermann R., Hürny C. Health related quality of life: a changing construct?. Qual Life Res 2004, 13:1187-1197.
11. Bernhard J., Maibach R., Thürlimann B., Sess C., Aapro M. Patients' estimation of overall treatment burden: why not ask the obvious?. J Clin Oncol 2002, 20:65-72.
12. Borson S., Scanlan J., Brush M., Vitaliano P., Dokmak A. The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry 2000, 15:1021-1027.
13. Scanlan J., Borson S. The Mini-Cog: receiver operating characteristics with expert and naive raters. Int J Geriatr Psychiatry 2001, 16:216-222.
14. Saliba D., Elliott M., Rubenstein L.Z., Solomon D.H., Young R.T., Kamberg C.J., et al. The vulnerable elders survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001, 49:1691-1699.
15. National Cancer Institute, US Institutes of Health. CTCAE website: [accessed 09.03.12]. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
16. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
17. Elkin E.B., Hurria A., Mitra N., Schrag D., Panageas K.S. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 2006, 24:2757-2764.
18. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
19. Le Deley M.C., Suzan F., Cutuli B., Delaloge S., Shamsaldin A., Linassier C., et al. Anthracyclines, mitoxantrone, radiotherapy and granulocyte colony-stimulating factor: risk factors for leukemia and Myelodysplastic Syndrome after breast cancer. J Clin Oncol 2007, 25:292-300.
20. Hayes D.F., Thor A.D., Dressler L.G., Weaver D., Edgerton S., Cowan D., et al. HER2 and response to paclitaxel in node positive breast cancer. N Engl J Med 2007, 357:1496-1506.
21. Crivellari D., Aapro M., Leonard R., von Minckwitz G., Brain E., Goldhirsch A., et al. Breast cancer in the elderly. J Clin Oncol 2007, 25:1882-1890.
22. Reimer T., Nitz U., Potenberg J., Conrad B., Graf H., Just M., et al. On behalf of the GBG/AGO/NOGGO/WSG study groups and the BIG: ICE Study: a prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). Eur J Cancer 2009, 7(2). (suppl):215, abstr 4003.
23. Reimer T., Joel B., von Minckwitz G., Potenberg J., Conrad B., Graf H., et al. On behalf of the GBG/AGO/NOGGO/WSG study groups and the BIG: quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. Eur J Cancer 2009, 7(2). (suppl):219, abstr 4016.
24. Nuzzo F., Morabito A., De Maio E., Di Rella F., Gravina A., Labonia V., et al. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. Crit Rev Oncol Hematol 2008, 66:171-180.
25. Crivellari D., Bonetti M., Castiglione-Gertsch M., Gelber R.D., Rudenstam C.M., Thürlimann B., et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000, 18:1412-1422.
26. Biganzoli L., Wildiers H., Oakman C., Marotti L., Loibl S., Kunkler I., et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012, 13:e148-e160.
27. La-Beck N.M., Zamboni B.A., Gabizon A., Schmeeda H., Amantea M., Gehrig P.A., et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 2012, 69:43-50.
28. Lyass O., Uziely B., Ben-Yosef R., Tzemach D., Heshing N.I., Lotem M., et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-1047.
29. Ganz P.A., Guadagnoli E., Landrum M.B., Lash T.L., Rakowski W., Silliman R.A. Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol 2003, 21:4027-4033.
30. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
31. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose " chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005, 23:939-952.
32. Luciani A., Ascione G., Bertuzzi C., Marussi D., Codecà C., Di Maria G., et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 2010, 28:2046-2050.
33. Launay-Vacher V., Spano J.P., Janus N., Gligorov J., Ray-Coquard I., Oudard S., et al. Renal Insufficiency and Anticancer Medications (IRMA) Study Group Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 2009, 70:124-133.
34. Muss H. Older women with breast cancer, slow progress, great opportunity, now is the time. J Clin Oncol 2011, 32:4608-4610.
35. Surveillance Epidemiology and End Results Program (SEER). http://seer.cancer.gov/index.html.